Across TCGA pan-cancer cohorts, PARL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PARL data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PARL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARL expression acts as an unfavorable survival marker.
STAD, UCEC, and SKCM are the cancer types where PARL Mutation most reproducibly stratifies survival.